title: Cefaclor and cefamandole as alternatives to spectinomycin in the treatment of men with uncomplicated gonorrhoea.
abstract: Between 25 December 1981 and 11 March 1982, 400 men with uncomplicated gonococcal urethritis were randomly assigned to one of four treatment regimens: spectinomycin 2 g intramuscularly (group A); cefamandole 1 g intramuscularly after probenecid 1 g orally (group B); cefaclor 3 g orally with probenecid 1 g orally (group C); and cefaclor 3 g orally (group D). The cure rates were 91 of 92 (98.9%) in group A, 68 of 96 (70.8%) in group B, 88 of 92 (95.8%) in group C, and 86 of 96 (89.6%) in group D. Cefaclor at a dose of 3 g given orally with 1 g probenecid appears to be an effective alternative to spectinomycin 2 g in the treatment of gonorrhoea in areas where strains of penicillinase producing Neisseria gonorrhoeae (PPNG) are prevalent.
mesh_terms: D002433:Cefaclor / Q000627:therapeutic use*; D002435:Cefamandole / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects / Q000201:enzymology; D010405:Penicillinase / Q000096:biosynthesis; D011339:Probenecid / Q000627:therapeutic use; D000198:Spectinomycin / Q000627:therapeutic use; D014526:Urethritis / Q000188:drug therapy
chemical_list: D002435:Cefamandole; D002433:Cefaclor; D000198:Spectinomycin; D010405:Penicillinase; D002506:Cephalexin; D011339:Probenecid